Stem cell companies using new US laws to provide unapproved products to seriously ill patients

cells
Credit: CC0 Public Domain

A new US law, designed to give terminally ill patients access to unproven drugs, is being invoked by stem cell companies to make unapproved stem cell products available, in a move that has an Australian expert concerned.

Professor John Rasko is one of a group of experts who are warning that the US Right to Try Act is being used by stem cell companies to provide unapproved products to seriously ill patients.

They say the use of this law by businesses selling unapproved stem cell products raises unsettling questions about their to evidence based care.

They say the US is already home to hundreds of businesses selling unproven stem cell interventions, and the weakening of laws makes it even more difficult for regulators to ensure the safety of these products.


Explore further

FDA targets clinics offering unapproved stem cell therapies

More information: Douglas Sipp et al. Stem Cell Businesses and Right to Try Laws, Cell Stem Cell (2019). DOI: 10.1016/j.stem.2019.08.012
Journal information: Cell Stem Cell

Provided by Cell Stem Cell
Citation: Stem cell companies using new US laws to provide unapproved products to seriously ill patients (2019, September 6) retrieved 23 September 2019 from https://medicalxpress.com/news/2019-09-stem-cell-companies-laws-unapproved.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more